149 related articles for article (PubMed ID: 38536911)
1. Recent advances in EZH2-based dual inhibitors in the treatment of cancers.
Yang X; Xu L; Yang L
Eur J Med Chem; 2023 Aug; 256():115461. PubMed ID: 37156182
[TBL] [Abstract][Full Text] [Related]
2. Select EZH2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT:AP-1 signaling.
Chomiak AA; Tiedemann RL; Liu Y; Kong X; Cui Y; Wiseman AK; Thurlow KE; Cornett EM; Topper MJ; Baylin SB; Rothbart SB
Sci Adv; 2024 Mar; 10(13):eadk4423. PubMed ID: 38536911
[TBL] [Abstract][Full Text] [Related]
3. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of EZH2 (Enhancer of Zeste Homolog 2) Attenuates Neuroinflammation via H3k27me3/SOCS3/TRAF6/NF-κB (Trimethylation of Histone 3 Lysine 27/Suppressor of Cytokine Signaling 3/Tumor Necrosis Factor Receptor Family 6/Nuclear Factor-κB) in a Rat Model of Subarachnoid Hemorrhage.
Luo Y; Fang Y; Kang R; Lenahan C; Gamdzyk M; Zhang Z; Okada T; Tang J; Chen S; Zhang JH
Stroke; 2020 Nov; 51(11):3320-3331. PubMed ID: 32933418
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Ezh2 redistributes bivalent domains within transcriptional regulators associated with WNT and Hedgehog pathways in osteoblasts.
Carrasco ME; Thaler R; Nardocci G; Dudakovic A; van Wijnen AJ
J Biol Chem; 2023 Sep; 299(9):105155. PubMed ID: 37572850
[TBL] [Abstract][Full Text] [Related]
6. Calcitonin gene-related peptide regulates spinal microglial activation through the histone H3 lysine 27 trimethylation via enhancer of zeste homolog-2 in rats with neuropathic pain.
An Q; Sun C; Li R; Chen S; Gu X; An S; Wang Z
J Neuroinflammation; 2021 May; 18(1):117. PubMed ID: 34020664
[TBL] [Abstract][Full Text] [Related]
7. Streamlined quantitative analysis of histone modification abundance at nucleosome-scale resolution with siQ-ChIP version 2.0.
Dickson BM; Kupai A; Vaughan RM; Rothbart SB
Sci Rep; 2023 May; 13(1):7508. PubMed ID: 37160995
[TBL] [Abstract][Full Text] [Related]
8. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Jang HJ; Hostetter G; Macfarlane AW; Madaj Z; Ross EA; Hinoue T; Kulchycki JR; Burgos RS; Tafseer M; Alpaugh RK; Schwebel CL; Kokate R; Geynisman DM; Zibelman MR; Ghatalia P; Nichols PW; Chung W; Madzo J; Hahn NM; Quinn DI; Issa JJ; Topper MJ; Baylin SB; Shen H; Campbell KS; Jones PA; Plimack ER
Clin Cancer Res; 2023 Jun; 29(11):2052-2065. PubMed ID: 36928921
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.
Kurahashi Y; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Yoshida-Sakai N; Fukuda-Kurahashi Y; Yamashita S; Hattori N; Nakamura H; Kawaguchi A; Ushijima T; Sueoka E; Kimura S
Blood Adv; 2023 Apr; 7(8):1545-1559. PubMed ID: 36516085
[TBL] [Abstract][Full Text] [Related]
11. Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas.
Li Y; Goldberg EM; Chen X; Xu X; McGuire JT; Leuzzi G; Karagiannis D; Tate T; Farhangdoost N; Horth C; Dai E; Li Z; Zhang Z; Izar B; Que J; Ciccia A; Majewski J; Yoon AJ; Ailles L; Mendelsohn CL; Lu C
Mol Cell; 2022 Oct; 82(20):3901-3918.e7. PubMed ID: 36206767
[TBL] [Abstract][Full Text] [Related]
12. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.
Zhang L; Li HT; Shereda R; Lu Q; Weisenberger DJ; O'Connell C; Machida K; An W; Lenz HJ; El-Khoueiry A; Jones PA; Liu M; Liang G
Cancer Lett; 2022 Nov; 548():215899. PubMed ID: 36087682
[TBL] [Abstract][Full Text] [Related]
13. Combinatorial Anticancer Drug Screen Identifies Off-Target Effects of Epigenetic Chemical Probes.
Barghout SH; Mann MK; Aman A; Yu Y; Alteen MG; Schimmer AD; Schapira M; Arrowsmith CH; Barsyte-Lovejoy D
ACS Chem Biol; 2022 Oct; 17(10):2801-2816. PubMed ID: 36084291
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]